Medicine and Dentistry
COVID-19
100%
Dyspnea
100%
Cohort Analysis
56%
Post-COVID-19
54%
Prevalence
54%
Toxic Epidermal Necrolysis
50%
STEVENS-JOHNSON SYNDROME
50%
Lung
50%
Sleep Disorder
50%
Sarcoidosis
50%
Sleep Quality
45%
Standardized Mortality Ratio
18%
All Cause Mortality
18%
UK Biobank
18%
Diseases
16%
Actigraphy
13%
Numeric Rating Scale
13%
Pittsburgh Sleep Quality Index
13%
Mortality Rate
12%
Primary Health Care
12%
Deterioration
9%
Muscle Weakness
9%
Secondary Care
6%
Cohort Effect
6%
Sex Ratio
6%
Pharmacology, Toxicology and Pharmaceutical Science
Sarcoidosis
100%
Prevalence
50%
Infliximab
50%
Toxic Epidermal Necrolysis
50%
Biological Product
50%
Stevens Johnson Syndrome
50%
Adalimumab
37%
Tofacitinib
37%
Syndrome
33%
Randomized Controlled Trial
25%
Tumor Necrosis Factor Inhibitor
25%
Tumor Necrosis Factor
25%
All Cause Mortality
18%
Standardized Mortality Ratio
18%
Diseases
16%
Anakinra
12%
Etanercept
12%
Lung Disease
12%
Mortality Rate
12%
Lung Sarcoidosis
12%
Sarilumab
12%
Golimumab
12%
Rituximab
12%
Skin Disease
12%
Ustekinumab
12%
Cohort Study
6%
Immunology and Microbiology
COVID-19
50%
Biological Product
50%
Sarcoidosis
50%
Infliximab
40%
Tofacitinib
30%
Adalimumab
30%
Cytotoxic T-Cell
28%
Tumor Necrosis Factor
20%
TNF Inhibitor
20%
Forced Vital Capacity
20%
T-Helper Cell
14%
Data Synthesis
10%
Arm
10%
Anakinra
10%
Rituximab
10%
Sarilumab
10%
Ustekinumab
10%
Golimumab
10%
Sample Size
10%
Etanercept
10%
Severe Acute Respiratory Syndrome
7%
Immunocompetent Cell
7%
Immune System
7%
Memory B Cell
7%
Peripheral Blood Mononuclear Cell
7%
CD4
7%
Natural Killer Cell
7%
Normal Human
7%
